Analyst Ratings For Acorda Therapeutics Inc (NASDAQ:ACOR)
Today, Acorda Therapeutics Inc (NASDAQ:ACOR) stock was downgraded by Goldman Sachs Group from Neutral to Sell.
There are 5 Hold Ratings, 3 Buy Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on Acorda Therapeutics Inc (NASDAQ:ACOR) is Hold with a consensus target price of $25.75 per share, a potential 35.31% upside.
Some recent analyst ratings include
- 12/11/2018-Acorda Therapeutics Inc (NASDAQ:ACOR) gets downgraded to Sell by Goldman Sachs Group
- 11/5/2018-Acorda Therapeutics Inc (NASDAQ:ACOR) had its Buy rating reiterated by HC Wainwright with a $30.00 price target
- 11/4/2018-Acorda Therapeutics Inc (NASDAQ:ACOR) had its Hold rating reiterated by Jefferies Financial Group with a $22.00 price target
- On 12/6/2018 Scopia Capital Management Lp, Major Shareholder, sold 43,801 with an average share price of $18.58 per share and the total transaction amounting to $813,822.58.
- On 12/3/2018 Andrew A Hindman, Insider, sold 753 with an average share price of $20.56 per share and the total transaction amounting to $15,481.68.
- On 12/3/2018 Ron Cohen, CEO, sold 3,620 with an average share price of $20.60 per share and the total transaction amounting to $74,572.00.
- On 12/3/2018 Scopia Capital Management Lp, Major Shareholder, sold 225,000 with an average share price of $20.51 per share and the total transaction amounting to $4,614,750.00.
- On 11/29/2018 Scopia Capital Management Lp, Major Shareholder, sold 50,000 with an average share price of $20.20 per share and the total transaction amounting to $1,010,000.00.
- On 11/26/2018 Lorin Randall, Director, sold 1,904 with an average share price of $19.98 per share and the total transaction amounting to $38,041.92.
- On 10/11/2018 Scopia Capital Management Lp, Major Shareholder, sold 143,576 with an average share price of $16.98 per share and the total transaction amounting to $2,437,920.48.
About Acorda Therapeutics Inc (NASDAQ:ACOR)
Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Women's Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Recent Trading Activity for Acorda Therapeutics Inc (NASDAQ:ACOR)
Shares of Acorda Therapeutics Inc closed the previous trading session at 19,03 +0,40 2,15 % with 19.24 shares trading hands.
